Neuroleptic Malignant Syndrome (NMS) is a rare but potentially lethal form of drug-induced hyperthermia. The objective of this paper is to provide data regarding early and suspected cases as well as offer guidelines for managing this condition. Knowledge of suspected cases will lead to early recognition and prompt management of this condition in the future.
Method
To address the gap in knowledge, we present 2 case reports of patients with early NMS-like symptoms. The case reports are followed by a brief review of the literature on differential diagnoses, risk factors, early signs and treatment data.
Conclusions
The most rational approach to treating NMS entails a hierarchy of interventions determined by the severity and progression of symptoms.
References
1.
DelayJ., PichotP., LemperiereT.Un neuroleptique majeur non-phenothiazine et non reserpinique, l'haloperidol, dans le traitement des psychoses.Ann Med Psychol1960; 118: 145–152.
KonikoffF., KuritzkyA., JerushalmiY., TheodorE.Neuroleptic malignant syndrome induced by a single injection of halperidol.Br Med J1984; 289: 1228–1229.
5.
SusmanV.L., AddonizioG.Reinduction of neuroleptic malignant syndrome by lithium.J Clin Psychopharmacol1987; 7: 339–341.
6.
GoulonM., Rohan-ChabotP., de ElkhaartD.Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: a report of two cases, Neurology1983; 33: 516–518.
7.
WeinbergS.E., TwerskilR.S.Neuroleptic malignant syndrome.Anesthesia and Analgesia1983; 62: 848–850.
8.
HendersonA., LongdonP.Fulminant metoclopramide-induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene.Aust N A J Med1991; 21: 742–743.
9.
Lenler-PertersonP., HansenB.D., HasselstromL.A rapidly progressing lethal case of neuroleptic malignant syndrome.Intensive Care Med1990; 16: 267–268.
10.
CaroffS.N., MannS.C.Neuroleptic malignant syndrome.Med Clin North Am1993; 77: 185–202.
11.
KeckP.E., PopeH.G., McElroyS.L.Frequency and presentation of neuroleptic malignant syndrome: a prospective study.Am J Psychiatry1987; 144: 1344–1346.
12.
WhiteD.A.C., RobinsA.H.Catatonia: harbinger of the neuroleptic malignant syndrome.Br J Psychiatry1991; 158: 419–421.
13.
WhiteD.A.C.Catatonia and the neuroleptic malignant syndrome: a single entity?Br J Psychiatry1992; 161: 558–560.
14.
WoodburyM.M., WoodburyM.A.Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome.J Am Acad Child Adolesc Psychiatry1992; 31: 1161–1164.
15.
AddonizioG., SusmanV.L.Neuroleptic malignant syndrome: a clinical approach. S.Louis MO: Mosby;1991.
FricchioneG.L.Neuroleptic catatonia and its relationship to psychogenic catatonia.Biol Psychiatry1985; 20: 304–313.
23.
LevinsonD.F., SimpsonG.M.Neuroleptic-induced extrapyramidal symptoms with fever: heterogeneity of the neuroleptic malignant syndrome.Arch Gen Psychiatry1986; 43: 839–848.
24.
SewellD., JesteD.V.Distinguishing neuroleptic malignant syndrome (NMS) from NMS-like acute medical illnesses: a study of 34 cases.J Neuropsychiatry1992; 4: 265–269.
25.
RosebushP.I., StewartT., MazurekM.F.The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care?Br J Psychiatry1991; 159: 709–712.
26.
SakkasP., DavisJ.M., HuaJ.Pharmacotherapy of neuroleptic malignant syndrome.Psychiatr Ann1991; 21: 157–164.
27.
SakkasP., DavisJ.M., JanucakP.G.Drug treatment of the neuroleptic malignant syndrome.Psychopharmacol Bull1991; 27: 381–384.
28.
ScheftnerW.A., ShulmanR.B.Treatment choice in neuroleptic malignant syndrome.Convuls Ther1992; 8: 267–279.
